MEDI9929 anti-TSLP mAb (AMG157) ( DrugBank: MEDI9929 )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
98好酸球性消化管疾患1

98. 好酸球性消化管疾患


臨床試験数 : 172 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2022-001294-31-DK
(EUCTR)
22/11/202204/10/2022Efficacy and Safety of Tezepelumab in Patients with Eosinophilic EsophagitisA Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Tezepelumab via APFS
Product Code: MEDI9929 anti-TSLP mAb (AMG157)
INN or Proposed INN: Tezepelumab
Other descriptive name: AMG 157
AstraZeneca ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
360Phase 3United States;Czechia;Slovakia;Greece;Finland;Spain;Austria;Israel;Italy;Canada;Belgium;Brazil;Denmark;Australia;Norway;Germany;Netherlands;China;Japan;New Zealand;Sweden